Abstract
Intranasal diamorphine is a rapid, effective, analgesia, with few side effects, giving it multiple advantages over other forms of analgesia. It is also importantly a needle free alternative, acceptable to children, parents and medical staff. Due to these advantages, it is thought to be increasingly used in Paediatric A, and possibly the most popular analgesia for severe acute pain, despite being unlicensed. However, there is little quantified data on the extent of its usage. In order to clarify this, we surveyed all 214 NHS A departments in England in Wales with the scenario of an uncomplicated long bone fracture. There were 116 responses (75% return rate), showing that 60% of departments were using intranasal opioid (90% diamorphine) as 1st line and 70% as 1st or 2nd line analgesia for long bone fracture. When compared to any other drugs used, intranasal diamorphine was nearly four times more likely to be used as the 1st line analgesia. Despite being unlicensed, intranasal diamorphine is widely accepted and the most commonly used analgesia in Paediatric A for acute pain in long bone fracture. This article also reviews the literature on intranasal diamorphine with an emphasis on Paediatric usage.
Keywords: Intranasal, diamorphine, paediatric, analgesia, otitis media, Opioids, oral morphine, nauseated, vomiting patient, fentanyl, morphine
Current Pediatric Reviews
Title: Intranasal Diamorphine Usage in Paediatric Accident and Emergency
Volume: 6 Issue: 3
Author(s): Maya Kerr and Ian Maconochie
Affiliation:
Keywords: Intranasal, diamorphine, paediatric, analgesia, otitis media, Opioids, oral morphine, nauseated, vomiting patient, fentanyl, morphine
Abstract: Intranasal diamorphine is a rapid, effective, analgesia, with few side effects, giving it multiple advantages over other forms of analgesia. It is also importantly a needle free alternative, acceptable to children, parents and medical staff. Due to these advantages, it is thought to be increasingly used in Paediatric A, and possibly the most popular analgesia for severe acute pain, despite being unlicensed. However, there is little quantified data on the extent of its usage. In order to clarify this, we surveyed all 214 NHS A departments in England in Wales with the scenario of an uncomplicated long bone fracture. There were 116 responses (75% return rate), showing that 60% of departments were using intranasal opioid (90% diamorphine) as 1st line and 70% as 1st or 2nd line analgesia for long bone fracture. When compared to any other drugs used, intranasal diamorphine was nearly four times more likely to be used as the 1st line analgesia. Despite being unlicensed, intranasal diamorphine is widely accepted and the most commonly used analgesia in Paediatric A for acute pain in long bone fracture. This article also reviews the literature on intranasal diamorphine with an emphasis on Paediatric usage.
Export Options
About this article
Cite this article as:
Kerr Maya and Maconochie Ian, Intranasal Diamorphine Usage in Paediatric Accident and Emergency, Current Pediatric Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339610793743903
DOI https://dx.doi.org/10.2174/157339610793743903 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
RNA Interference-Based Gene Expression Strategies Aimed at Sustained Therapeutic Inhibition of HIV
Current Topics in Medicinal Chemistry Hydrogen Sulfide Generation in Mammals: The Molecular Biology of Cystathionine-β-Synthase (CBS) and Cystathionine-γ-Lyase (CSE)
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacotranscriptomic Biomarkers in Glucocorticoid Treatment of Pediatric Inflammatory Bowel Disease
Current Medicinal Chemistry Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach
Current Alzheimer Research Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Hepatic Effects of Duloxetine-II: Spontaneous Reports and Epidemiology of Hepatic Events
Current Drug Safety Triheptanoin Supplementation to Ketogenic Diet Curbs Cognitive Impairment in APP/PS1 Mice Used as a Model of Familial Alzheimer’s Disease
Current Alzheimer Research Targeting RAS Signaling Pathways in Juvenile Myelomonocytic Leukemia
Current Drug Targets Biospecific Interaction Analysis (BIA) as a Tool for the Design and Development of Gene Transcription Modifiers
Current Medicinal Chemistry - Anti-Cancer Agents The Implication of Platelet Activating Factor in Cancer Growth and Metastasis: Potent Beneficial Role of PAF-Inhibitors and Antioxidants
Infectious Disorders - Drug Targets Effect of Recombinant Human Thymosin-α1, an Immuno-Modulating Peptide with 28 Amino Acids, on the Activity of Cytochrome P450s
Drug Metabolism Letters Combat Pneumococcal Infections: Adhesins as Candidates for Protein- Based Vaccine Development
Current Drug Targets Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y12 antagonists
Current Drug Targets Transcriptional Regulation of the p53 Tumor Suppressor Gene: A Potential Target for Cancer Therapeutics?
Recent Patents on DNA & Gene Sequences Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer
Current Pharmaceutical Design Novel Biomarkers for Lupus Nephritis in the “OMICS” Era
Current Medicinal Chemistry New Agents – Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing
Current Cancer Therapy Reviews Biomarkers for Predicting the Immunomodulatory Properties of Probiotics
Recent Patents on Biomarkers Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Editorial [Hot Topic: Paracrine Mechanisms, Signaling and Epigenetics in Repairing Damaged Tissue]
Recent Patents on Regenerative Medicine